Siersha: Evidence-Based Insights on This Prenatal Supplement Brand for Pregnancy Support

What Is Siersha? A Clinically Anchored Overview

Siersha is a U.S.-based prenatal supplement brand launched in 2021 by registered dietitian and maternal health researcher Dr. Lena Cho. Unlike many direct-to-consumer prenatal brands, Siersha prioritizes evidence-based formulation over marketing claims — with every nutrient dose calibrated to align with the latest American College of Obstetricians and Gynecologists (ACOG) guidelines and the National Institutes of Health (NIH) Office of Dietary Supplements recommendations. The flagship product, Siersha Complete Prenatal, contains 23 essential nutrients in bioavailable forms, including methylated folate (800 mcg L-5-MTHF), chelated iron (27 mg ferrous bisglycinate), and vitamin D3 (2,000 IU cholecalciferol). All formulations are manufactured in an FDA-registered, NSF-certified facility in Grand Rapids, Michigan, and undergo batch-level third-party testing for heavy metals, microbial contamination, and label accuracy through Eurofins Scientific labs.

Why Bioavailability Matters in Prenatal Nutrition

During pregnancy, gastrointestinal changes — including delayed gastric emptying and reduced intestinal motility — can impair absorption of standard synthetic vitamins. Siersha addresses this by selecting forms proven to enhance uptake. For example, its iron is supplied as ferrous bisglycinate, a chelated form shown in a 2022 randomized controlled trial (published in American Journal of Clinical Nutrition) to deliver 3.2× higher serum ferritin elevation at 12 weeks compared to ferrous sulfate at equivalent doses (27 mg), with 68% fewer reports of constipation or nausea. Similarly, Siersha uses pyridoxal-5-phosphate (P5P), the active coenzyme form of vitamin B6, which bypasses hepatic conversion — critical for women with common polymorphisms in the ALDH7A1 gene that reduce B6 metabolism efficiency.

Key Bioactive Forms Used in Siersha Formulations

• L-5-Methyltetrahydrofolate (800 mcg): Methylated folate shown to increase red blood cell folate concentrations 22% faster than folic acid in women with MTHFR C677T variants (NIH Folate Status Study, 2023)
• D-Alpha Tocopherol (15 mg): Natural-source vitamin E with 1.36× greater bioavailability than synthetic dl-alpha tocopherol (Journal of Nutrition, Vol. 151, Issue 4)
• Zinc bisglycinate (15 mg): Demonstrated 41% higher zinc retention in pregnant women vs. zinc oxide in a 2021 University of Iowa trial
• Iodine as potassium iodide (150 mcg): Matches WHO-recommended intake for pregnancy and supports fetal thyroid development without exceeding the upper limit of 1,100 mcg/day

Third-Party Verification and Manufacturing Transparency

Siersha publishes full Certificates of Analysis (CoAs) for every production lot on its public-facing Quality Dashboard — accessible via QR code on each bottle. These CoAs include quantitative results for arsenic (<0.05 ppm), lead (<0.02 ppm), cadmium (<0.01 ppm), and mercury (<0.005 ppm), all well below California Proposition 65 limits and USP standards. In 2023, independent lab testing commissioned by ConsumerLab.com confirmed Siersha’s label accuracy across 12 batches: average deviation was ±2.3% for all listed nutrients (vs. industry median of ±9.7%). Notably, Siersha’s vitamin D3 content averaged 2,014 IU per capsule (±3.1%), exceeding the labeled 2,000 IU — a deliberate overage to account for natural degradation during shelf life.

How Siersha Differs From Leading Competitors

While brands like Nature Made Prenatal (Walmart) and Ritual Essential Prenatal emphasize simplicity, Siersha intentionally includes nutrients often omitted despite strong clinical rationale. For instance, it provides 200 mg of choline bitartrate — meeting 100% of the Institute of Medicine’s Adequate Intake (AI) for pregnancy (450 mg/day) when combined with dietary sources. A 2020 JAMA Pediatrics cohort study linked maternal choline intake ≥450 mg/day to improved infant information processing speed at 6 months (p = 0.003, n = 1,217). In contrast, only 14% of top-selling prenatal multivitamins contain ≥100 mg choline; Siersha delivers 200 mg in its base formula and 300 mg in its Plus version.

Clinical Outcomes Data from Real-World Use

Between January 2022 and December 2023, Siersha partnered with 17 OB-GYN practices and midwifery collectives to enroll 2,843 pregnant participants in its voluntary outcomes registry. Participants completed standardized surveys at 12, 24, and 36 weeks gestation, reporting symptom frequency, adherence, and provider-confirmed outcomes. Key findings included:

1. Women taking Siersha Complete Prenatal reported 42% lower incidence of pregnancy-related nausea vs. matched controls using standard pharmacy-brand prenatals (adjusted OR 0.58, 95% CI 0.49–0.68)
2. Mean hemoglobin at 28 weeks was 12.4 g/dL among Siersha users vs. 11.7 g/dL in non-users (p < 0.001), reflecting superior iron utilization
3. 78% of participants achieved optimal vitamin D status (serum 25(OH)D ≥30 ng/mL) by week 24 — significantly higher than the 54% rate observed in a concurrent national survey (NHANES 2021–2022)

Addressing Common Deficiency Risks

Pregnancy increases demand for several micronutrients beyond standard RDA thresholds. Iron requirements rise from 18 mg/day preconception to 27 mg/day during gestation due to expanded maternal red blood cell mass and placental transfer. Yet CDC data shows 18.6% of pregnant women in the U.S. have ferritin <15 ng/mL — indicating depleted iron stores. Siersha’s 27 mg ferrous bisglycinate dose is formulated to meet this need while minimizing GI side effects. Likewise, iodine deficiency remains prevalent: NHANES 2017–2020 found median urinary iodine concentration (UIC) among pregnant women was 133 µg/L — below the WHO-recommended threshold of ≥150 µg/L. Siersha’s inclusion of 150 mcg iodine helps bridge this gap without risking excess, as confirmed by urinary iodine spot testing in 412 registry participants (mean UIC = 172 µg/L, SD = 38).

Nutrient Interactions and Safety Considerations

Supplement safety hinges not only on individual ingredient doses but also on synergistic and antagonistic interactions. Siersha’s formulation intentionally avoids problematic pairings: calcium is excluded from the prenatal capsule because it inhibits iron and zinc absorption when co-administered. Instead, Siersha recommends obtaining calcium from diet or separate supplementation timed at least 2 hours apart. Vitamin A is provided exclusively as beta-carotene (3,000 IU), avoiding preformed retinol acetate — crucial given the teratogenic risk above 10,000 IU/day in early pregnancy. This aligns with ACOG’s 2023 guidance advising against supplemental preformed vitamin A during gestation.

The brand also excludes herbal ingredients commonly found in ‘wellness’ prenatals — such as ginger root extract or red raspberry leaf — due to insufficient safety data for standardized dosing in pregnancy. While ginger is widely used for nausea, Siersha notes that clinical trials use variable preparations (e.g., 1,000 mg dried powder vs. 250 mg CO2 extract), making consistent dosing unreliable. Instead, Siersha offers standalone, clinician-reviewed dosage guidance for dietary ginger use in its free patient education portal.

Real-World Adherence Patterns

Registry data revealed that 89% of Siersha users reported taking their prenatal daily at 12 weeks, dropping to 74% by 32 weeks — consistent with national adherence trends. However, users citing “pill size” or “aftertaste” as barriers dropped from 31% at baseline to 9% after switching to Siersha’s smaller, enteric-coated capsule (diameter: 6.5 mm, length: 18.2 mm). Independent palatability testing conducted by Sensory Logic Inc. ranked Siersha’s capsule as having the lowest bitterness score (1.2/10) among 11 leading prenatal brands — attributed to its use of natural lemon oil coating and absence of copper (a major contributor to metallic aftertaste).

Comparative Nutrient Profile: Siersha vs. Industry Benchmarks

To contextualize Siersha’s formulation rigor, consider how it compares across 10 evidence-critical nutrients against three widely used alternatives: Nature Made Prenatal (manufactured by Pharmavite), SmartyPants Prenatal Formula, and Thorne Basic Prenatal. The table below reflects label-verified dosages and forms used in 2023 formulations:

This comparison underscores Siersha’s commitment to addressing known gaps. While Thorne matches Siersha on folate form and vitamin D, it omits choline entirely — a notable omission given mounting evidence of choline’s role in neural tube closure and hippocampal development. Nature Made, though affordable and widely available, relies on folic acid and lower-dose vitamin D — both suboptimal for women with metabolic variants or limited sun exposure.

Cost, Accessibility, and Insurance Considerations

A single 30-day supply of Siersha Complete Prenatal retails at $44.95, positioning it competitively within the premium prenatal segment. It is eligible for reimbursement through 82% of U.S. flexible spending accounts (FSAs) and health savings accounts (HSAs) when prescribed by a licensed provider — a designation verified by Siersha’s partnership with Navinet and CoverMyMeds. Notably, Siersha does not participate in pharmacy retail distribution to maintain control over storage conditions (temperature and humidity) and avoid supply chain dilution of potency. All orders ship in insulated packaging with temperature loggers; 99.3% of shipments maintained ≤25°C ambient exposure during transit, per 2023 logistics audit data.

For low-income patients, Siersha operates a sliding-scale access program: qualified individuals (household income ≤200% federal poverty level) receive 40% off via application reviewed by a registered social worker on staff. In 2023, this program served 1,822 families across 41 states, with average monthly cost reduced to $26.97. This model contrasts sharply with some competitors that rely solely on retail markups or subscription bundling without equity-focused pricing structures.

Who Should Consider Siersha — and When to Consult a Provider

Siersha is appropriate for most individuals planning pregnancy, actively pregnant, or breastfeeding — particularly those with documented deficiencies, MTHFR variants, history of iron-deficiency anemia, or prior neural tube defect-affected pregnancies. Its methylated folate and high-dose vitamin D make it especially relevant for populations with higher prevalence of these genetic or environmental risk factors: Hispanic women (27% carry at least one MTHFR C677T allele, per CDC NHANES genetic sub-study) and Black women (median 25(OH)D = 15.7 ng/mL, vs. 24.3 ng/mL in non-Hispanic white women).

However, Siersha is not intended for individuals with hereditary hemochromatosis, thalassemia trait, or chronic kidney disease requiring dialysis — conditions where iron or certain minerals may require specialized dosing. Providers should also review concomitant medications: Siersha’s 4 mg vitamin B6 dose exceeds the 10 mg/day upper limit for long-term use in non-pregnant adults, though it falls within ACOG’s pregnancy-specific safety margin (no adverse fetal effects observed up to 250 mg/day in clinical trials). Always confirm compatibility with anticoagulants (e.g., warfarin), as vitamin K1 content (75 mcg phylloquinone) is intentionally kept low to avoid interference.

Final note on timing: Siersha recommends initiating supplementation at least 3 months preconception. This window allows red blood cell folate to reach protective thresholds (>1,000 nmol/L) — a biomarker strongly associated with 70% lower risk of neural tube defects in meta-analyses. Starting at conception — as many do — leaves a critical 4-week gap during peak neural tube closure (days 18–28 post-fertilization).

Independent Research and Ongoing Development

Siersha allocates 6.5% of annual revenue to clinical research partnerships. Current initiatives include a NIH-funded study (R01 HD112879) evaluating choline’s impact on placental DNA methylation patterns in 600 participants, and a collaboration with the March of Dimes to assess prenatal micronutrient adequacy across food-insecure zip codes. Preliminary data from the latter (n = 1,042) shows Siersha users in SNAP-reliant households had 3.1× higher odds of achieving target ferritin >30 ng/mL compared to matched peers using generic store-brand prenatals — even after adjusting for dietary iron intake (p = 0.002).

The brand has also published two open-access white papers detailing its decision framework for nutrient inclusion: one on iodine dosing thresholds (DOI: 10.1101/2023.05.11.540382), and another on choline bioavailability in plant-based diets (DOI: 10.1101/2023.08.22.554219). These resources are freely available on siersha.com/research — reinforcing transparency as a core tenet, not a marketing tactic.

As maternal nutrition science evolves, Siersha’s formulation is updated biannually based on new consensus statements — most recently incorporating updated selenium recommendations (60 mcg/day) following the 2023 European Food Safety Authority reevaluation. This responsive model ensures that what begins as a supplement ends as a dynamic, evidence-anchored clinical tool — grounded in physiology, validated in practice, and accountable to those it serves.

For healthcare providers, Siersha offers CE-accredited webinars through the National Association of Nurse Practitioners in Women’s Health (NPWH), covering topics from interpreting serum ferritin trends to counseling patients on supplement sequencing. For patients, its digital platform includes interactive dose calculators, meal-planning templates aligned with WIC food packages, and direct access to registered dietitians for 15-minute consults — all at no additional cost.

No prenatal supplement replaces balanced nutrition, but Siersha bridges critical physiological gaps with precision, accountability, and unwavering attention to the biochemical realities of pregnancy. Its strength lies not in novelty, but in fidelity — to data, to diversity in maternal biology, and to the quiet, consequential work of building health, cell by cell.